QA1 and QA3 are the derivatives of substituted 1, 3-dimethyl-1H-quinoxalin-2-ones that may
selectively antagonize P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells …

The effect of 24 newly synthesized quinoline derivatives on tumor cell multidrug resistance
(MDR) was examined in vitro. At low concentrations, these compounds enhanced the …

Development of multidrug resistance (MDR) during chemotherapy is a fundamental obstacle
associated with cancer care. Prior studies have identified (2-(4-methoxyphenyl)-4 …

Multidrug resistance (MDR) mediated by the over expression of drug efflux protein P-
glycoprotein (P-gp) is one of the major impediments to successful treatment of cancer. P-gp …

Multidrug resistance (MDR) is still the main barrier to attaining effective results with
chemotherapy. Discovery of new chemo‐reversal agents is needed to overcome MDR. Our …

The development of multidrug-resistance (MDR) in neoplastic cells is often responsible for
the therapy failure and poor outcome of a number of human cancers. MDR may be …

Multidrug resistance (MDR) caused by P-glycoprotein (P-gp, ABCB1, MDR-1) transporter
over-expression in cancer cells substantially limits the effectiveness of chemotherapy. 1, 4 …

Purpose: The ATP-binding cassette transporters P-glycoprotein (Pgp) and BCRP are
implicated in multidrug resistance (MDR) of many tumors. Multi-targeted inhibitors such as …

Abstract P‐glycoprotein (P‐gp)‐mediated multidrug resistance (MDR) is a major obstacle for
successful cancer chemotherapy. Based on our previous study, 17 novel compounds with …

Abstract P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major impediment
for clinical cancer therapy. 19 novel aromatic amides with triazole-core as MDR reversal …